vistusertib + ibrutinib

**Vistusertib + ibrutinib** is a combination of two investigational small molecule inhibitors intended for the treatment of B-cell malignancies, particularly diffuse large B-cell lymphoma (DLBCL). Vistusertib is a dual inhibitor of mammalian target of rapamycin complexes 1 and 2 (mTORC1/2), targeting key cellular pathways involved in cell growth and survival. Ibrutinib selectively and irreversibly inhibits Bruton’s tyrosine kinase (BTK), a critical enzyme in B-cell receptor signaling, resulting in impaired proliferation and migration of malignant B cells. The combination is designed to target complementary signaling pathways that drive B-cell malignancy and resistance to single-agent therapy. Clinical studies have evaluated various dosing schedules for vistusertib in combination with BTK inhibitors in relapsed/refractory lymphoma, but clinical activity has been modest.

Other names

vistusertibibrutinib